Your session is about to expire
← Back to Search
Talimogene Laherparepvec + Pembrolizumab for Skin Cancer
Study Summary
This trial is studying how well talimogene laherparepvec and pembrolizumab work in treating patients with stage III-IV melanoma. Biological therapies use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and pembrolizumab may work better in treating patients with melanoma by shrinking the tumor.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 3 trial • 31 Patients • NCT01368276Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many participants are currently enrolled in this experiment?
"This trial is no longer actively recruiting, as the latest update occurred on October 5th 2022. For those seeking alternatives, 816 and 978 investigations are presently enrolling patients with melanoma or Talimogene Laherparepvec respectively."
What other experiments have been conducted regarding the efficacy of Talimogene Laherparepvec?
"Talimogene Laherparepvec was initially trialled at City of Hope in the year 2010, with 263 clinical studies having been completed to date. Presently there are 978 active examinations being conducted around the world, many of which are taking place in Cincinnati, Ohio."
Are there any open slots for volunteers in this research project?
"This clinical trial is no longer accepting participants since its last update on October 5th 2022. If you are searching for other studies, 816 trials involving melanoma and 978 investigations focused on Talimogene Laherparepvec are actively recruiting patients."
Has the FDA sanctioned Talimogene Laherparepvec for therapeutic use?
"As this trial is a Phase 2, there are some safety data points but no efficacy information. Thus, the Power team have assigned Talimogene Laherparepvec a score of two on the 1 - 3 scale."
In what localities can participants access this experiment?
"Currently, 20 medical centres are hosting this trial. Among these locations are Cincinnati, West Bloomfield and Columbus among other cities. To minimize the burden of travel on participants, we encourage selecting a site near you for clinical participation."
What types of medical conditions is Talimogene Laherparepvec commonly employed to combat?
"Talimogene Laherparepvec is a commonly used treatment for malignant neoplasms. Additionally, it has been shown to be beneficial in cases of unresectable melanoma, microsatellite instability high and diseases that have worsened due to chemotherapy."
Share this study with friends
Copy Link
Messenger